Get the Stockscreener App
9.66
0.00%
0.00
After Hours:
9.39
-0.27
-2.80%
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates - MSN
(ALGS) Long Term Investment Analysis - Stock Traders Daily
Aligos Therapeutics Presents Positive Data at APASL 2025 - The Manila Times
Clinical Trial Success: Aligos' Dual Breakthroughs in Liver Disease Show 100% Efficacy - StockTitan
Ten option delistings on March 24th - TipRanks
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) - Armenian Reporter
Learn to Evaluate (ALGS) using the Charts - Stock Traders Daily
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics Expands Team with Strategic Stock Option Package - StockTitan
HC Wainwright Issues Negative Outlook for ALGS Earnings - Defense World
Financial Comparison: Achilles Therapeutics (NASDAQ:ACHL) vs. Aligos Therapeutics (NASDAQ:ALGS) - Defense World
H.C. Wainwright cuts Aligos stock target to $70, maintains Buy By Investing.com - Investing.com Australia
H.C. Wainwright cuts Aligos stock target to $70, maintains Buy - Investing.com India
Aligos Therapeutics (NASDAQ:ALGS) Price Target Lowered to $70.00 at HC Wainwright - Defense World
Aligos Therapeutics Faces Challenges in Developing Hepatitis B Treatments Amidst Industry Competition - TipRanks
Aligos Therapeutics Advances Pipeline Amid Financial Challenges - TipRanks
Aligos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aligos Therapeutics reports fourth-quarter and full-year 2024 results -March 10, 2025 at 10:48 am EDT - Marketscreener.com
ALIGOS THERAPEUTICS Earnings Results: $ALGS Reports Quarterly Earnings - Nasdaq
Aligos Therapeutics reports Q4 EPS ($13.08) vs ($5.50) last year - TipRanks
Aligos Therapeutics, Inc. SEC 10-K Report - TradingView
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Aligos Q4 Earnings: $105M Raise Backs Promising HBV Drug Results - StockTitan
Earnings Scheduled For March 10, 2025 - Benzinga
Aligos Therapeutics (ALGS) to Release Quarterly Earnings on Monday - Defense World
ALIGOS THERAPEUTICS Earnings Preview: Recent $ALGS Insider Trading, Hedge Fund Activity, and More - Nasdaq
How the (ALGS) price action is used to our Advantage - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 23.7% in February - Defense World
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025 - The Manila Times
Will Aligos Therapeutics Q4 Results Reveal Progress in Liver Disease Pipeline? - StockTitan
Reviewing Aligos Therapeutics (NASDAQ:ALGS) & Editas Medicine (NASDAQ:EDIT) - Defense World
(ALGS) Trading Report - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Decline in Short Interest - MarketBeat
Aligos Therapeutics looks to raise $105 million in private placement - MSN
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Down 13.2% in January - Defense World
Aligos Therapeutics Announces $105 Million Private Placement FinancingAligos Therapeutics, Inc. (NASDAQ: ALGS) recently disclosed a Securities Purchase Agreement engagement entailing a Private Placement offering. The agreement includes the issuan - Defense World
Aligos Therapeutics, Inc. announced that it expects to receive $105.003206 million in funding - Marketscreener.com
Aligos Therapeutics secures $105 million in private placement By Investing.com - Investing.com Canada
Aligos Therapeutics secures $105 million in private placement - MSN
Aligos Therapeutics Secures $105M in Private Placement - TipRanks
Aligos Therapeutics rises after $105 million private placement - TradingView
Aligos Therapeutics announces $105M private placement financing - TipRanks
Aligos Therapeutics Announces $105 Million Private Placement Financing - The Manila Times
Major Funding Alert: Aligos Lands $105M Investment for Game-Changing Hepatitis B Drug Development - StockTitan
Trading (ALGS) With Integrated Risk Controls - Stock Traders Daily
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely - Yahoo Canada Finance
Aligos Therapeutics patents new inhibitors of PD-1, PD-L1 or PD-1/PD-L1 interaction - BioWorld Online
PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? - Yahoo Finance
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update - MarketBeat
Aligos Therapeutics Appoints Lesley Ann Calhoun as COO - TipRanks
1.46%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):